Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, Hadjadj S, Gillard P, Górriz JL, Idorn T, Ji L, Mahaffey KW, Perkovic V, Rasmussen S, Schmieder RE, Pratley RE, Tuttle KR.
Mann JFE, et al. Among authors: ji l.
Nat Med. 2024 Jun 24. doi: 10.1038/s41591-024-03133-0. Online ahead of print.
Nat Med. 2024.
PMID: 38914124